Drug Profile
SLV 338
Alternative Names: SLV338Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Solvay Pharmaceuticals
- Developer Abbott Healthcare Products; Abbott Laboratories
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in United Kingdom (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in European Union
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie